XVIVO presents interim report January-June 2021

Second quarter 2021 (Apr 1 – Jun 30)
• Net sales amounted to SEK 59.3 million (30.4), corresponding to an increase of 95 percent in SEK and 116 percent in local currencies. Net sales of non-durable goods amounted to SEK 56.3 million (28.0), corresponding to an increase of 101 percent in SEK and 124 percent in local currencies.
• Machine perfusion accounted for 52 percent (39) of net sales.
• Net sales in Business area Thoracic amounted to SEK 49.9 million (30.3) and Abdominal SEK 9.4 million (-).
• Adjusted operating profit before depreciation and amortization (EBITDA) amounted to SEK 8.4 million (-1.0), corresponding to an adjusted EBITDA margin of 14 percent (-3). Reported EBITDA amounted to SEK -1.5 million (-5.5), corresponding to an EBITDA margin of -3 percent (-18).
• Adjusted operating profit (EBIT) amounted to SEK 0.6 million (-8.2). Reported EBIT amounted to SEK -9.3 million (-12.7).
• Net profit amounted to SEK -8.9 million (-16.0). Earnings per share amounted to SEK -0.31 (-0.60).
• Cash and cash equivalents at the end of the quarter amounted to SEK 311.4 million (140.0).
 
Significant events during the quarter
• A 510(k) application for Kidney Assist Transport was filed with the FDA in the US.
• In the UK, NICE issued guidelines recommending EVLP as the standard arrangement for preservation of lungs.
• The number of shares and votes in XVIVO Perfusion AB (publ) increased by 33,261 following exercise of warrants under incentive program 2019/2021.

The period 2021 (Jan 1 – Jun 30)
• Net sales amounted to SEK 117.6 million (76.9), corresponding to an increase of 53 percent in SEK and 68 percent in local currencies. Net sales of non-durable goods amounted to SEK 111.1 million (72.2), corresponding to an increase of 54 percent in SEK and 70 percent in local currencies.
• Machine perfusion accounted for 52 percent (34) of net sales.
• Net sales in Business area Thoracic amounted to SEK 96.3 million (76.8) and Abdominal SEEK 21.3 million (-).
• Adjusted operating profit before depreciation and amortization (EBITDA) amounted to SEK 14.7 million (4.1), corresponding to an adjusted EBITDA margin of 12 percent (5). Reported EBITDA amounted to SEK 9.7 million (2.1), corresponding to an EBITDA margin of 8 percent (3).
• Adjusted operating profit (EBIT) amounted to SEK -1.2 million (-10.7). Reported EBIT amounted to SEK -6.2 million (-12.7).
• Net profit amounted to SEK -2.9 million (-9.5). Earnings per share amounted to SEK -0.10 (-0.36).
• Cash and cash equivalents at the end of the period amounted to SEK 311.4 million (140.0).
 
Significant events during the period
• An article published in The New England Journal of Medicine, shows that oxygenated perfusion of donated liver before transplantation has a significant positive impact on the outcomes after transplantation.
• First patients transplanted in the Australian heart preservation study.
 
CEO comment
“The impact of the pandemic on hospitals varies between countries, which means that the rate at which transplant centers are returning to normal activity levels varies. The US, XVIVO’s largest market, was quick to introduce an effective vaccination program, and the number of transplants for all major organs increased sharply in 2021 compared to 2020 and is now just above 2019 numbers. Other markets, such as certain European countries, started to recover later on, which has led to more patients waiting for new organs and the demand for transplants has never been higher. XVIVO’s vision that “Nobody should die waiting for a new organ” has become even more relevant during the pandemic.“